Lipocine Inc

NASDAQ:LPCN  
0.41
0.00 (-0.22%)
5:47:33 PM EDT: $0.45 +0.04 (+11.03%)
Earnings Announcements

Lipocine Announces Strategic Realignment And Forward Focus On Treating CNS Disorders

Published: 09/26/2022 12:12 GMT
Lipocine Inc (LPCN) - Lipocine Announces Strategic Realignment and Forward Focus on Treating Cns Disorders.
Lipocine Inc Says Co to Explore Strategic Partnerships and Other Opportunities for Non-core Assets.
Lipocine Inc Says Had $37.4 Million of Unrestricted Cash, Cash Equivalents and Marketable Investment Securities, As of June 30.
Lipocine Inc Says Believes Cash Will Be Sufficient to Support Operations and Capital Expenditure Until at Least September 30, 2023.
Revenue is expected to be $1.31 Million
Adjusted EPS is expected to be -$0.03

Next Quarter Revenue Guidance is expected to be $0.98 Million
Next Quarter EPS Guidance is expected to be -$0.03

More details on our Analysts Page.